Media coverage about BeyondSpring (NASDAQ:BYSI) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. BeyondSpring earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news headlines about the company an impact score of 47.3238005218245 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

BYSI has been the topic of a number of recent analyst reports. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of BeyondSpring in a report on Monday, August 21st. Zacks Investment Research upgraded shares of BeyondSpring from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Rodman & Renshaw boosted their price target on shares of BeyondSpring from $43.00 to $50.00 and gave the company a “buy” rating in a report on Friday, July 14th. Finally, Maxim Group initiated coverage on shares of BeyondSpring in a report on Tuesday, August 22nd. They set a “buy” rating and a $52.00 price target on the stock.

Shares of BeyondSpring (NASDAQ:BYSI) opened at 36.51 on Tuesday. The firm’s market cap is $834.03 million. The stock’s 50 day moving average is $38.87 and its 200-day moving average is $32.05. BeyondSpring has a 12-month low of $16.55 and a 12-month high of $48.49.

TRADEMARK VIOLATION NOTICE: “BeyondSpring (BYSI) Getting Somewhat Favorable News Coverage, Study Shows” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at

BeyondSpring Company Profile

BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).

Insider Buying and Selling by Quarter for BeyondSpring (NASDAQ:BYSI)

Receive News & Stock Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related stocks with our FREE daily email newsletter.